-
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)
What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Deciphering B Cell Cancers With a Rituximab Biosimilar(Post)The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the
Alternative Complement Pathway: Activation, Regulation, and Significance(Post)Immunology · Complement SystemThe Alternative Complement PathwayThe alternative pathway is one of three routes that activate complement — an antibody-independent, always-on surveillance system d
Insulin Signaling and RTK: An Overview(Post)Cell Signalling · MetabolismInsulin Signalling & Receptor Tyrosine KinasesInsulin controls metabolism and growth through the insulin receptor — a receptor tyrosine kinase that branches into the
Allorecognition, Transplant Rejection & GvHD(Page) Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
Microglia and Neuroinflammation(Page) Blood Coagulation Signaling Pathways: A Critical Overview(Post)Cell Signalling · HaemostasisBlood Coagulation Signaling Pathways: A Critical OverviewBlood coagulation is a tightly regulated cascade in which circulating clotting factors are sequentially activated
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
B-Cell Receptor Signalling and the Germinal Centre Reaction(Post)The germinal centre is where antibody quality is made. A naive B cell that binds antigen does not become a source of protective, high-affinity IgG by accident. It passes through a tightly choreograph
Understanding CD16: A Comprehensive Overview(Post)CD16, also known as FcγRIII (Fc gamma receptor III), plays a crucial role in the immune system, serving as a receptor for the Fc region of immunoglobulin G (IgG). This receptor is a key player in
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Eosinophils, IL-5 and the Type 2 Granulocyte Axis(Page) Macrophage Phagocytosis & the CD47–SIRPα Checkpoint(Page) Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
One Integrin Chain, Two Partners, Brain or Gut(Post)A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a
Understanding CD16: A Comprehensive Overview(Post)CD16, also known as FcγRIII (Fc gamma receptor III), plays a crucial role in the immune system, serving as a receptor for the Fc region of immunoglobulin G (IgG). This receptor is a key player in
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements(Post)Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel